Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endpoint Selection Could Help Determine The NASH Race

Executive Summary

Sponsors in the hotly pursued and yet untapped field of non-alcoholic steatohepatitis think that selection of different primary or co-primary endpoints could help differentiate their programs in the competitive space.


Related Content

Combination Strategies A Common Thread In NASH R&D
Intercept Seeks Long-Term Data To Build Ocaliva Market In PBC
Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure
Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study
NASH Race No More Clear After AASLD Than Before
Intercept’s Phase III Endpoints May Not Apply To Other Firms’ NASH Programs
With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018
Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate
Intercept rollercoaster continues with NASH, PBC updates
Searching For Surrogate Endpoints Requires Teamwork


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts